Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 59.705 USD 1.14% Market Closed
Market Cap: 3.7B USD
Have any thoughts about
Rhythm Pharmaceuticals Inc?
Write Note

Intrinsic Value

RYTM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RYTM stock under the Base Case scenario is 55.247 USD. Compared to the current market price of 59.705 USD, Rhythm Pharmaceuticals Inc is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RYTM Intrinsic Value
55.247 USD
Overvaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Rhythm Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RYTM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RYTM?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Rhythm Pharmaceuticals Inc

Provide an overview of the primary business activities
of Rhythm Pharmaceuticals Inc.

What unique competitive advantages
does Rhythm Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Rhythm Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Rhythm Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Rhythm Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Rhythm Pharmaceuticals Inc.

Provide P/S
for Rhythm Pharmaceuticals Inc.

Provide P/E
for Rhythm Pharmaceuticals Inc.

Provide P/OCF
for Rhythm Pharmaceuticals Inc.

Provide P/FCFE
for Rhythm Pharmaceuticals Inc.

Provide P/B
for Rhythm Pharmaceuticals Inc.

Provide EV/S
for Rhythm Pharmaceuticals Inc.

Provide EV/GP
for Rhythm Pharmaceuticals Inc.

Provide EV/EBITDA
for Rhythm Pharmaceuticals Inc.

Provide EV/EBIT
for Rhythm Pharmaceuticals Inc.

Provide EV/OCF
for Rhythm Pharmaceuticals Inc.

Provide EV/FCFF
for Rhythm Pharmaceuticals Inc.

Provide EV/IC
for Rhythm Pharmaceuticals Inc.

Show me price targets
for Rhythm Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Rhythm Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Rhythm Pharmaceuticals Inc?

What are the Net Income projections
for Rhythm Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Rhythm Pharmaceuticals Inc?

What are the EPS projections
for Rhythm Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Rhythm Pharmaceuticals Inc?

What are the EBIT projections
for Rhythm Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Rhythm Pharmaceuticals Inc?

Compare the revenue forecasts
for Rhythm Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Rhythm Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Rhythm Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Rhythm Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Rhythm Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Rhythm Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Rhythm Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Rhythm Pharmaceuticals Inc.

Provide ROE
for Rhythm Pharmaceuticals Inc.

Provide ROA
for Rhythm Pharmaceuticals Inc.

Provide ROIC
for Rhythm Pharmaceuticals Inc.

Provide ROCE
for Rhythm Pharmaceuticals Inc.

Provide Gross Margin
for Rhythm Pharmaceuticals Inc.

Provide Operating Margin
for Rhythm Pharmaceuticals Inc.

Provide Net Margin
for Rhythm Pharmaceuticals Inc.

Provide FCF Margin
for Rhythm Pharmaceuticals Inc.

Show all solvency ratios
for Rhythm Pharmaceuticals Inc.

Provide D/E Ratio
for Rhythm Pharmaceuticals Inc.

Provide D/A Ratio
for Rhythm Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Rhythm Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Rhythm Pharmaceuticals Inc.

Provide Quick Ratio
for Rhythm Pharmaceuticals Inc.

Provide Current Ratio
for Rhythm Pharmaceuticals Inc.

Provide Cash Ratio
for Rhythm Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Rhythm Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Rhythm Pharmaceuticals Inc?

What is the current Free Cash Flow
of Rhythm Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Rhythm Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Rhythm Pharmaceuticals Inc

Current Assets 340.3m
Cash & Short-Term Investments 298.4m
Receivables 19.3m
Other Current Assets 22.6m
Non-Current Assets 23.2m
PP&E 4.4m
Intangibles 6.4m
Other Non-Current Assets 12.5m
Current Liabilities 97.6m
Accounts Payable 4.9m
Accrued Liabilities 54.8m
Other Current Liabilities 37.9m
Non-Current Liabilities 113.3m
Long-Term Debt 109.2m
Other Non-Current Liabilities 4m
Efficiency

Earnings Waterfall
Rhythm Pharmaceuticals Inc

Revenue
112.5m USD
Cost of Revenue
-12.8m USD
Gross Profit
99.7m USD
Operating Expenses
-365.2m USD
Operating Income
-265.5m USD
Other Expenses
4m USD
Net Income
-261.5m USD

Free Cash Flow Analysis
Rhythm Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Rhythm Pharmaceuticals reported robust Q3 results with IMCIVREE revenue reaching $33.3 million, a 14% increase from the previous quarter. U.S. sales accounted for $23.3 million, up 8% sequentially, driven by rising patient reimbursements. International revenue hit $10 million—a 35% increase—reflecting expanding markets. Cash usage decreased to $22.6 million, and guidance for operating expenses was lowered to $245-$255 million. Looking ahead, the company plans to share Phase III data on hypothalamic obesity in early 2025. Additionally, the FDA review for expanding IMCIVREE's indication to children as young as two is expected by December 26, 2024, promising more patient engagement.

What is Earnings Call?
Fundamental Scores

RYTM Profitability Score
Profitability Due Diligence

Rhythm Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
34/100
Profitability
Score

Rhythm Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

RYTM Solvency Score
Solvency Due Diligence

Rhythm Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
64/100
Solvency
Score

Rhythm Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RYTM Price Targets Summary
Rhythm Pharmaceuticals Inc

Wall Street analysts forecast RYTM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RYTM is 71.678 USD with a low forecast of 58.58 USD and a high forecast of 88.2 USD.

Lowest
Price Target
58.58 USD
2% Downside
Average
Price Target
71.678 USD
20% Upside
Highest
Price Target
88.2 USD
48% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RYTM?

Click here to dive deeper.

Dividends

Rhythm Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RYTM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RYTM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

RYTM News

Other Videos

Profile

Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.7B USD

Dividend Yield

0%

Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2017-10-05. The firm is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. The company is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. The company targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

Contact

MASSACHUSETTS
Boston
222 Berkeley St Fl 12
+18572644280.0
www.rhythmtx.com

IPO

2017-10-05

Employees

140

Officers

Chairman, President & CEO
Dr. David P. Meeker M.D.
CFO & Treasurer
Mr. Hunter C. Smith M.B.A.
Chief Technical Officer
Mr. Joseph Shulman
Executive VP & Head of International
Mr. Yann Mazabraud
Executive VP & Head of North America
Ms. Jennifer Lee
Corporate Controller, Principal Accounting Officer & Executive Director
Mr. Christopher German
Show More
Chief Scientific Officer
Dr. Alastair Garfield Ph.D.
Head of Investor Relations & Corporate Communications
Mr. David Connolly
Senior VP & General Counsel
Mr. Jim Flaherty
Vice President of Sales & Marketing
Ms. Sarah Ryan
Show Less

See Also

Discover More
What is the Intrinsic Value of one RYTM stock?

The intrinsic value of one RYTM stock under the Base Case scenario is 55.247 USD.

Is RYTM stock undervalued or overvalued?

Compared to the current market price of 59.705 USD, Rhythm Pharmaceuticals Inc is Overvalued by 7%.

Back to Top